ReviewGastroenterology report2026
Microbiome-derived cancer: the catabolism of bilirubin to urobilin in the liver-gut axis and its consequences.
Review in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally and is associated with factors, such as obesity, inflammation, and metabolic disorders. Bilirubin, a byproduct of heme degradation, is increasingly recognized as a signaling molecule with antioxidant properties that protect against obesity by reducing oxidative stress, decreasing inflammation, and activating the nuclear receptor PPARα, which enhances fat metabolism and utilization. The gut microbiome converts bilirubin to urobilinogen via bilirubin reductase, which is then rapidly oxidized to urobilin, thereby influencing colon cancer outcomes. Urobilin may contribute to CRC by being linked to insulin resistance and inflammation in obese individuals, and it could cause DNA damage. Additionally, it may serve as a biomarker for CRC, obesity, insulin-resistant diabetes, and irritable bowel syndrome. This review covers enzymes in the heme oxygenase pathway (HMOX, BVR, UGT1A1) that regulate bilirubin production and excretion, as well as the microbiome-driven breakdown of bilirubin into urobilinogen and its subsequent oxidation to urobilin. It highlights the inverse relationships among CRC, obesity, and inflammation and suggests that urobilin pathways influence CRC risk. Restoring bilirubin's protective signaling and reducing circulating urobilin could open new avenues for prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.